SmallCapReview.com: Small Cap Stocks to Watch - IMAX, VICL, ADLS, CSIQ

Jul 17, 2008 (M2 PRESSWIRE via COMTEX) -- IMAX | Quote | Chart | News | PowerRating -- IMAX Corporation (Nasdaq: IMAX | Quote | Chart | News | PowerRating) Closed at $6.88. Today announced a joint venture agreement to install up to four IMAX theatres in Japan. The agreement marks IMAX's second international joint venture deal, as the Company aligns itself with top exhibitors worldwide with its new IMAX Digital theatre system. To date, IMAX has signed contracts for more than 180 IMAX Digital theatre systems, with approximately 50 expected to be installed by the end of 2008. IMAX is currently a focus stock at SmallCapReview.com.

The announcement follows a record-setting movie event in Japan, where 25,000 people, the largest IMAX audience ever for a single screening, enjoyed the Japanese premiere of Speed Racer: The IMAX Experience on June 29 at the Tokyo Dome. The Tokyo Dome, which is a traditional venue for concerts and sporting events, was converted into a huge IMAX theatre for the event.

What They Do: IMAX Corporation is one of the world's leading digital entertainment and technology companies. The worldwide IMAX network is among the most important and successful theatrical distribution platforms for major event Hollywood films around the globe, with IMAX theatres delivering the world's best cinematic presentations using proprietary IMAX, IMAX 3D, and IMAX DMR technology.

How They Trade: IMAX has a 52 week high of $7.94 and a 52 week low of $3.72. Volume averages approximately 154K shares a day.

Vical Incorporated (Nasdaq: VICL) Closed at $3.43. Today announced a breakthrough with preliminary clinical trial data demonstrating that DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. DNA vaccines are fundamentally different from conventional vaccines because they do not contain any part of the virus itself, and may offer compelling advantages in response to a pandemic outbreak because of significantly reduced development and manufacturing times.

What They Do: Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor.

How They Trade: VICL has a 52 week high of $5.47 and a 52 week low of $3.00. Volume averages approximately 59K shares a day.

Advanced Life Sciences Holdings (Nasdaq: ADLS) Closed at $1.00. Today announced that the United Kingdom's Defence Science and Technology Laboratory ("Dstl") will evaluate the developmental compound ALS-886 as a treatment for chemically induced lung injury. ALS-886 is a small molecule therapeutic that, in preclinical studies, has demonstrated efficacy in reducing and preventing tissue damage in the lungs. Dstl has experience modeling lung injury and will conduct animal efficacy studies to measure the ability of ALS-886 to improve the clinical outcome following lung injury that results from the inhalation of chemicals that damage the lung surface.

What They Do: Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage development for the treatment of respiratory tract infections including CAP.

How They Trade: ADLS has a 52 week high of $2.85 and a 52 week low of $0.67. Volume averages approximately 128K shares a day.

Canadian Solar (Nasdaq: CSIQ) Closed at $35.65. Today announced further details regarding its follow-on public offering of common shares. A total of 3,500,000 common shares are being sold in the Offering at a price of $34.00 per share. In addition, the underwriters have been granted a 30-day option to purchase up to 525,000 common shares from the Company solely to cover over-allotments. The Company's common shares are traded on the Nasdaq Global Market under the ticker symbol ''CSIQ.''

What They Do: Canadian Solar, Inc., together with its subsidiaries, engages in the design, development, manufacture, and marketing of solar module products that convert sunlight into electricity for various uses.

How They Trade: CSIQ has a 52 week high of $51.80 and a 52 week low of $6.50. Volume averages approximately 3.2MK shares a day.

About SmallCapReview

Copyright SmallCapReview. SmallCapReview.com has been a leading site for news on small-cap stocks since 1999. SmallCapReview has built a loyal opt-in following for their investor products by providing a newsletter at no cost, sent to subscribers, highlighting select small-cap stocks, to register and automatically be entered to win a Free Blackberry Pearl visit http://www.smallcapreview.com/subscribe.htm

CONTACT: SmallCapReview WWW: http://www.smallcapreview.com

M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index